Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline
MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) said it has closed its acquisition of iRenix Medical, Inc., adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline as the company seeks to expand its presence in eye care and enter the retina market.
On an investor call discussin
NASDAQ:TARS